Skip to main content
Premium Trial:

Request an Annual Quote

Japanese Drug Maker to Acquire Proteomics Shop ActivX for $21M

NEW YORK, Dec. 3 (GenomeWeb News) - Kyorin Pharmaceutical of Tokyo will buy proteomics company ActivX Biosciences for $21 million, the company said yesterday.

 

Kyorin will create a US subsidiary and merge it with ActivX, which will then become a wholly owned subsidiary of Kyorin. An acquisition date was not disclosed.

 

Kyroin and ActivX, of La Jolla, Calif., have collaborated since 2002 in a Type II diabetes discovery program, and in January expanded their activities to include metabolic disorders. ActivX also has collaborations with Pfizer, Gilead, and an undisclosed additional pharma partner.

 

ActivX uses a core proteomics technology, licensed from Scripps, that consists of fluorescent chemical affinity probes that bind to the active sites of a specific class of proteins.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.